IRs of MACE and malignancies in pts with PsA and PsO receiving tofacitinib, stratified by HxCAD, BL 10-yr ASCVD risk and BL MetS
| MACE | Malignancies | |||||||
|---|---|---|---|---|---|---|---|---|
| PsA | PsO | PsA | PsO | |||||
| n/N[n1] | IR (95% CI) | n/N[n1] | IR (95% CI) | n/N[n1] | IR (95% CI) | n/N[n1] | IR (95% CI) | |
| HxCAD | ||||||||
| Yes | 1/39[0] | 0.97 (0.02, 5.38) | 3/93[0] | 1.49 (0.31, 4.36) | 0/39[0] | 0.00 (0.00, 3.52) | 0/93[0] | 0.00 (0.00, 1.83) |
| No | 5/744[5] | 0.25 (0.08, 0.59) | 20/3570[10] | 0.22 (0.13, 0.34) | 15/744[10] | 0.75 (0.42, 1.24) | 60/3570[26] | 0.66 (0.51, 0.85) |
| BL 10-yr ASCVD risk category | ||||||||
| High risk (≥20%) | 1/35[1] | 1.26 (0.03, 7.01) | 7/179[4] | 1.67 (0.67, 3.43) | 1/35[1] | 1.26 (0.03, 7.03) | 15/179[10] | 3.57 (2.00, 5.89) |
| Intermediate risk(≥7.5–<20%) | 2/121[2] | 0.62 (0.07, 2.23) | 9/716[6] | 0.50 (0.23, 0.95) | 8/121[7] | 2.46 (1.06, 4.86) | 23/716[9] | 1.28 (0.81, 1.92) |
| Borderline risk(≥5–<7.5%) | 1/91[1] | 0.42 (0.01, 2.32) | 2/400[0] | 0.19 (0.02, 0.67) | 2/91[1] | 0.83 (0.10, 3.01) | 5/400[1] | 0.47 (0.15, 1.09) |
| Low risk (<5%) | 1/487[1] | 0.08 (0.00, 0.42) | 2/2241[0] | 0.03 (0.00, 0.13) | 4/487[1] | 0.30 (0.08, 0.77) | 17/2241[6] | 0.30 (0.17, 0.47) |
| BL MetS | ||||||||
| Yes | 5/320 | 0.60 (0.20, 1.40) | 10/1197 | 0.34 (0.16, 0.63) | 10/320 | 1.20 (0.58, 2.21) | 26/1197 | 0.89 (0.58, 1.31) |
| No | 1/463 | 0.08 (0.00, 0.44) | 13/2466 | 0.20 (0.11, 0.35) | 5/463 | 0.40 (0.13, 0.92) | 34/2466 | 0.54 (0.37, 0.75) |
Follow-up time calculated up to the day of the first event and subject to risk period of 28 days beyond the last dose of study drug.
CI, confidence interval; N, total pts; n, pts with MACE/malignancies; n1, pts with MACE/malignancies and BL MetS.